RxDoctor Payments Data

Christine Ko, MD

Internal Medicine · Lexington, KYNPI 1174568455

Payments from drug & device makers

$9,022in general payments, 2019–2025

Across 537 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$877
  • Boehringer Ingelheim$786
  • Novo Nordisk$765
  • Pfizer$587
  • Amgen$513
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$9,006100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,022 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$132,927
Medicare patients
186
Services billed
1,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide82$94,404
OzempicSemaglutide39$59,212
JardianceEmpagliflozin40$53,546
EliquisApixaban17$27,046
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog31$20,048
Synjardy XrEmpagliflozin/Metformin Hcl14$18,924
MyrbetriqMirabegron13$16,764
XareltoRivaroxaban12$13,360
FarxigaDapagliflozin Propanediol15$12,811
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$7,993
Rosuvastatin Calcium239$3,419
Atorvastatin Calcium381$3,230
Levothyroxine Sodium285$3,098
SynthroidLevothyroxine Sodium59$2,619
Ezetimibe94$2,423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$877$94,40482 claims
Boehringer IngelheimJardiance, Synjardy Xr$786$72,47054 claims
Novo NordiskOzempic$765$59,21239 claims
PfizerEliquis$587$27,04617 claims
Astellas Pharma US IncMyrbetriq$401$16,76413 claims
Johnson & JohnsonXarelto$339$13,36012 claims
AstraZenecaFarxiga$442$12,81115 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$68$3,098285 claims
AbbVieSynthroid$1,332$2,61959 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →